UK telehealth comparison

Comparing UK hair loss telehealth services

A clinician-published, MHRA-compliant comparison of WMG Meds against the main UK direct-to-consumer hair loss services. Verifiable structural criteria only: GMC Specialist Register status, MHRA Drug Safety Update disclosure, named-clinician transparency, physical clinic presence, and GPhC pharmacy regulation.

What this guide is (and is not)

This guide is published by WMG Meds, a CQC-registered UK private medicines service. We compare ourselves to the main UK direct-to-consumer hair loss services on verifiable structural criteria, not on subjective opinion. We acknowledge what each competitor does well. We name when a competitor is the better fit for a specific patient. We do not denigrate. The comparison meets the ASA CAP Code requirements for medical advertising (3.33 on comparisons; 12.12 on prescription-only medicines).

All claims here are verifiable. Where we cite a clinician's GMC registration status, the GMC register entry link is provided so you can verify it yourself. Where we cite MHRA Drug Safety Update disclosure, we link the gov.uk source. Where we cite competitor pricing or clinical leadership, we record the date of observation.

How we score

Five verifiable criteria: GMC Specialist Register entry, MHRA April 2024 + May 2026 Drug Safety Update disclosure, named-clinician transparency, physical clinic presence, GPhC pharmacy regulation. None of these are subjective. None require trusting our opinion.

What WMG offers that the direct-to-consumer competitors structurally cannot

• Medical Director on the GMC Specialist Register for Plastic Surgery (Dr Sebastian Deme, GMC 7130749, since 7 June 2017). The competitors\' most credentialled hair-loss clinicians hold MRCGP, MBBS or BSSM, appropriate qualifications, but not Specialist Register entries in the surgical field.
• Full MHRA Drug Safety Update disclosure across all product pages: both the 29 April 2024 update (psychiatric and sexual side effects, persistence after discontinuation) and the 11 May 2026 update (strengthened wording, extension to dutasteride, patient alert cards). Yellow Card scheme prominently linked.
• Three-site diagnose-prescribe-operate stack: WMG Health (blood testing on wmghealthcare.com), WMG Meds (prescribing here), WMG London (surgery on wmglondon.com). Single Harley Street address, single CQC-registered clinical provider.
• Physical Harley Street clinic at 134 Harley Street, London W1G 7JY, patients can attend for blood draw or surgical consultation. Hims, Sons, Manual and Numan are fully digital.
• CC-BY editorial Standards on wmghealthcare.com (Pre-Hair-Transplant Bloodwork Standard) and machine-readable /.well-known/corrections.json, citable open clinical references no UK competitor publishes.

When fully-digital telehealth is the right fit

If you have a confirmed diagnosis, no risk factors that warrant in-person assessment, and want the lowest possible monthly cost with a frictionless online experience, a fully-digital service such as Hims, Sons or Numan is a reasonable choice. We say so explicitly. Direct-to-consumer telehealth is regulated, the major UK brands all use GPhC-registered partner pharmacies, and most of them name at least one GMC-registered clinician.

WMG is built for patients who want a named UK Specialist Register clinician, full regulatory disclosure (including the MHRA-acknowledged risk of persistent sexual or psychiatric side effects), and the option to add bloods or in-person Harley Street consultation. If that is not your priority, a different service may suit you better.

How to verify any UK hair-loss prescriber yourself

1. Find the clinician\'s GMC number on the service\'s about or team page. Reputable services will publish this.
2. Look up the GMC register at gmc-uk.org. Check current registration status and any Specialist Register entry.
3. Find the dispensing pharmacy\'s GPhC registration in the service\'s terms or privacy policy. Look it up at pharmacyregulation.org.
4. Check MHRA Drug Safety Updates at gov.uk/drug-safety-update. For finasteride and dutasteride, the 29 April 2024 and 11 May 2026 updates set the current expected counselling standard.
5. Read the service\'s side-effect counselling page. If it says side effects "always resolve on stopping", it is not aligned with current MHRA wording on persistence.

Want to start with WMG Meds?

Begin a short assessment and we\'ll have a GMC-registered doctor review your case.

Get started →